Table 1.
Demographic Features of HIV-1-Infected Individuals and Controls
| |
HIV-1-infected individuals |
|
|
|---|---|---|---|
| Item | With opportunistic infections (n=10) | Without opportunistic infections (n=39) | Healthy controls (n=21) |
| Age: median (range) | 25 (20–63) | 36 (20–61) | 24 (19–47) |
| Male:Female | 6:4 | 25:14 | 8:13 |
| Viral load in RNA copies/ml plasma: median (range) | 83,700 (734–231,000) | 17,750 (<50–750,000) | N/A |
| With HAARTa: without HAART | 4:6 | 30:9 | N/A |
| CD4+ T cells/μl peripheral bloodb: median (range) | 130 (4–406) | 330 (14–950) | 646 (460–1143) |
a
Patients in HAART treatment were using combinations of nucleotide and nucleoside reverse transcriptase inhibitors (abacavir, lamivudine, didanosine, stavudine, and zidovudine), nonnucleoside reverse transcriptase inhibitors (efavirenz and nevirapine), and protease inhibitors (lopinavir, fosamprenavir, amprenavir, nelfinavir, and saquinavir).
b
CD4+ T cell counts under 200 cells/μl; were receiving fluconazol, acyclovir, and TMS as prophylactic.
HAART, highly active antiretroviral therapy; NA, not applicable.